Patients with CAE, n (%) | BR | B-mono |
| n = 275 | n = 100 |
Duration of the line of therapy (days), mean [median] | 121 [116] | 75 [56] |
Blood and lymphatic system disorders | 201 (73.1) | 67 (67.0) |
Anemia (deficiency and hemolytic) | 73 (26.5) | 35 (35.0) |
Neutropenia and febrile neutropenia | 112 (40.7) | 37 (37.0) |
Lymphadenopathy | 62 (22.5) | 18 (18.0) |
Thrombocytopenia (including autoimmune) | 78 (28.4) | 25 (25.0) |
Cardiac disorders | 75 (27.3) | 21 (21.0) |
Arrhythmia (including atrial fibrillation and flutter) | 58 (21.1) | 12 (12.0) |
Cardiac failure congestive | 35 (12.7) | 11 (11.0) |
Endocrine disorders, i.e., hypothyroidism | 47 (17.1) | 6 (6.0) |
Gastrointestinal disorders | 162 (58.9) | 48 (48.0) |
Nausea/vomiting | 97 (35.3) | 34 (34.0) |
General disorders | 139 (50.5) | 47 (47.0) |
Chills/pyrexia (with and without fever) | 50 (18.2) | 21 (21.0) |
Malaise and fatigue | 78 (28.4) | 25 (25.0) |
Hepatobiliary disorders | 1 (0.4) | 0 (0.0) |
Injury, poisoning and procedural complications | 34 (12.4) | 21 (21.0) |
Allergic reaction + application/administration site reaction | 30 (10.9) | 20 (20.0) |
Metabolism and nutrition disorders | 114 (41.5) | 28 (28.0) |
Dehydration | 54 (19.6) | 18 (18.0) |
Hypokalaemia | 25 (9.1) | 4 (4.0) |
Musculoskeletal and connective tissue disorders | 69 (25.1) | 17 (17.0) |
Neoplasms | 97 (35.3) | 24 (24.0) |
Nervous system disorder | 50 (18.2) | 10 (10.0) |
Renal and urinary disorders | 71 (25.8) | 15 (15.0) |
Psychiatric disorders | 35 (12.7) | 12 (12.0) |
Respiratory, thoracic and mediastinal disorders | 136 (49.5) | 43 (43.0) |
Cough | 60 (21.8) | 19 (19.0) |
Dyspnea | 69 (25.1) | 20 (20.0) |
Skin and subcutaneous tissue disorders | 26 (9.5) | 5 (5.0) |
Vascular disorders | 156 (56.7) | 39 (39.0) |
Hypertension | 134 (48.7) | 31 (31.0) |
Infections | 141 (51.3) | 39 (39.0) |